Cwm, LLC Insmed Inc Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Insmed Inc stock. As of the latest transaction made, Cwm, LLC holds 1,450 shares of INSM stock, worth $101,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,450

Previous 1,570 7.64%

Holding current value

$101,500

Previous $105,000 0.95%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$62.0 - $79.01 $7,440 - $9,481	-120 Reduced 7.64%	1,450 $106,000
Q2 2024 Jul 09, 2024	BUY	$22.0 - $69.71 $3,410 - $10,805	155 Added 10.95%	1,570 $105,000
Q1 2024 Apr 05, 2024	BUY	$25.72 - $29.94 $360 - $419	14 Added 1.0%	1,415 $38,000
Q4 2023 Feb 01, 2024	SELL	$23.42 - $31.74 $889 - $1,206	-38 Reduced 2.64%	1,401 $43,000
Q3 2023 Oct 11, 2023	BUY	$19.86 - $26.93 $873 - $1,184	44 Added 3.15%	1,439 $36,000
Q2 2023 Aug 03, 2023	SELL	$16.44 - $21.1 $3,518 - $4,515	-214 Reduced 13.3%	1,395 $29,000
Q1 2023 Apr 28, 2023	BUY	$16.26 - $21.73 $1,056 - $1,412	65 Added 4.21%	1,609 $27,000
Q4 2022 Feb 01, 2023	BUY	$16.98 - $23.15 $22,702 - $30,951	1,337 Added 645.89%	1,544 $31,000
Q3 2022 Oct 27, 2022	BUY	$20.88 - $28.21 $1,064 - $1,438	51 Added 32.69%	207 $4,000
Q2 2022 Jul 28, 2022	BUY	$17.07 - $25.71 $409 - $617	24 Added 18.18%	156 $3,000
Q1 2022 Apr 21, 2022	BUY	$20.42 - $28.13 $2,409 - $3,319	118 Added 842.86%	132 $3,000
Q4 2021 Jan 31, 2022	SELL	$25.89 - $33.45 $957 - $1,237	-37 Reduced 72.55%	14 $0
Q1 2020 Apr 28, 2020	SELL	$13.63 - $33.98 $2,903 - $7,237	-213 Reduced 80.68%	51 $1,000
Q4 2019 Jan 27, 2020	BUY	$16.12 - $24.98 $4,255 - $6,594	264 New	264 $6,000

Others Institutions Holding INSM

# of Institutions

467

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.48B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account